Biomaterial Database

[Therapy of chronic viral hepatitis with recombinant interferon-alpha]. 1992

P Ferenci

Klinischen Abteilung Gastroenterologie und Hepatologie, Universitätsklinik für Innere Medizin IV, Wien.

Long term treatment with interferon alpha is the only established therapy for chronic viral hepatitis so far. Depending on the type of viral hepatitis the response rate to interferon alpha is between 15 and 40%. These results can be improved by an appropriate selection of patients and possibly by combination therapy with other immunomodulatory and antiviral substances. The optimal dose in chronic hepatitis B is 5 Mega Units (MU) interferon alpha every other day for 6 months and in hepatitis C 3 MU every other day over 6 months.

UI	MeSH Term	Description	Entries
D007370	Interferon Type I	Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA).	Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D011994	Recombinant Proteins	Proteins prepared by recombinant DNA technology.	Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003699	Hepatitis D	INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS, a defective RNA virus that can only infect HEPATITIS B patients. For its viral coating, hepatitis delta virus requires the HEPATITIS B SURFACE ANTIGENS produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	Amazon Black Fever,Black Fever, Amazon,Delta Hepatitis,Delta Infection,Delta Superinfection,Hepatitis, Delta,Labrea Disease,Infection, Delta,Superinfection, Delta,Delta Superinfections,Disease, Labrea,Diseases, Labrea,Fever, Amazon Black,Hepatitides, Delta,Infections, Delta,Labrea Diseases,Superinfections, Delta
D006508	Hepatitis Antibodies	Immunoglobulins raised by any form of viral hepatitis; some of these antibodies are used to diagnose the specific kind of hepatitis.	Antibodies, Hepatitis
D006521	Hepatitis, Chronic	INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors.	Chronic Hepatitis,Cryptogenic Chronic Hepatitis,Hepatitis, Chronic, Cryptogenic,Hepatitis, Chronic Active,Hepatitis, Chronic Persistent,Chronic Active Hepatitis,Chronic Hepatitis, Cryptogenic,Chronic Persistent Hepatitides,Chronic Persistent Hepatitis,Hepatitis, Cryptogenic Chronic
D006526	Hepatitis C	INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.	Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

P Ferenci

Recombinant alpha 2c-interferon therapy in fulminant viral hepatitis.

October 1987, Journal of hepatology,

P Ferenci

[Antiviral therapy with recombinant alpha-interferon in chronic B virus hepatitis].

June 1990, Revista medica de Chile,

P Ferenci

[Long-term therapy in chronic hepatitis C with recombinant alpha interferon].

January 1994, Rivista europea per le scienze mediche e farmacologiche = European review for medical and pharmacological sciences = Revue europeenne pour les sciences medicales et pharmacologiques,

P Ferenci

[Treatment of chronic viral hepatitis with recombinant interferon-alfa].

July 1992, Orvosi hetilap,

P Ferenci

[Therapy of chronic viral hepatitis with interferon].

January 1994, Der Internist,

P Ferenci

[Current status of treatment for chronic viral hepatitis using recombinant interferon alpha].

July 1994, Deutsche medizinische Wochenschrift (1946),

P Ferenci

[Interferon alpha and chronic viral hepatitis].

September 1994, La Revue du praticien,